Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Sitagliptin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more

Conditions: Asthma
Interventions: A006 DPI, Placebo DPI, Proventil® MDI; Drug · Other
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more

Conditions: Postpartum, Neuromuscular Adaptations, Abdominal Muscles, Pelvic Floor Dysfunctions, Physical Activity
Interventions: Progressive exercise, Active Straight Leg Raise Test, Active Straight Leg Raise Fatigue Task, Lower Extremity Strength Testing, Ultrasound imaging of abdominal wall, Pelvic Floor Muscle Strength Testing, Pelvic Floor Muscle Endurance Testing; Other · Diagnostic Test
Lead sponsor: Carroll University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 2,409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 22
States / cities: Downey, California • Huntington Beach, California • San Diego, California + 18 more

Conditions: Glioblastoma
Interventions: Trans Sodium Crocetinate plus SOC, Standard of Care (SOC); Drug · Other
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Irvine, California • Redwood City, California • Santa Monica, California + 10 more

Conditions: Infertility
Interventions: Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator, Placebo Vaginal gel with applicator, Placebo injectable solution; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Tempe, Arizona • Encino, California • Los Angeles, California + 20 more

Conditions: Dravet Syndrome
Interventions: ETX101; Drug
Lead sponsor: Encoded Therapeutics; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Miami, Florida + 8 more

Conditions: Covid19
Interventions: Observational; Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 7 more

Conditions: Pain, Postoperative, Postoperative Hemorrhage
Interventions: Bupivacaine, Fibrin Sealant; Drug · Biological
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 12 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Oral Bacteria Levels in the Mouth
Interventions: Total Flavor option 1, Total Flavor option 2, Placebo toothpaste: Crest Cavity Protection toothpaste; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 22 Years to 58 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose); Biological · Other
Lead sponsor: Meissa Vaccines, Inc.; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more

Conditions: Multiple Sclerosis
Interventions: 4-session Relaxation Training, 4-session Behavioral Activation, 4-session Cognitive Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pneumococcal Disease
Interventions: Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5, Candidate-6, Candidate Control, 13vPnC, PCV15; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 18
States / cities: Tustin, California • Walnut Creek, California • Milford, Connecticut + 12 more

Conditions: Aortic Valve Stenosis, Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Replacement
Interventions: EMBLOK™ Embolic Protection System ("EMBLOK EPS"), SENTINEL™ Cerebral Protection System; Device
Lead sponsor: Emblok, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 23
States / cities: Chandler, Arizona • Orange, California • Sacramento, California + 20 more

Conditions: Painful Diabetic Neuropathy
Interventions: NRD135SE.1, Placebo; Drug · Other
Lead sponsor: James P. Rathmell, MD; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: San Diego, California • Clermont, Florida • Gainesville, Florida + 18 more

Conditions: Healthy Volunteer, Becker Muscular Dystrophy
Interventions: EDG-5506, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Eosinophilic Asthma
Interventions: Etokimab, Placebo; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more

Conditions: Type 2 Diabetes Treated With Insulin
Interventions: PAZ320; Drug
Lead sponsor: Boston Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Jefferson, New Hampshire

Conditions: Epilepsy
Interventions: Memory Tasks, Attention/arousal tasks, Language tasks, Visuospatial tasks, Auditory Tasks, Brain Stimulation, Social Emotional Task, Recording of facial expressions, Judgement/Impulsivity Task; Other · Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Stress, Obesity, Overeating
Interventions: Nutritional Counseling, Mindfulness Intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteer
Interventions: Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Hemorrhoids
Interventions: Bupivacaine HCl, SKY0402; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Birmingham, Alabama • Montgomery, Alabama • Pasadena, California + 16 more

Conditions: Serious Infections Due to Known or Suspected Gram-positive Pathogens
Interventions: TD-1607, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV/AIDS, Health Knowledge, Attitudes, Practice, STI
Interventions: Trans Women Connected, General Health App; Behavioral
Lead sponsor: ETR Associates; Other
Eligibility: 18 Years to 49 Years
Enrollment: 574 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Scotts Valley, California

Search by objective public record fields.

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation

Postpartum Exercise Intervention

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study

Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage

Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR

EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA

A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes

Human Intracranial Electrophysiology

Decreasing Stress and Improving Self-control With "Stress in Control" (Sync) Training

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

TD-1607 SAD Study in Healthy Subjects

Evaluation of the Trans Women Connected Mobile App for Changes in Sexual Health-related Behavior Among Transgender Women